Abstract
Background: positive impact of early tumor shrinkage(ETS) on long-term survival has been studied in the context of on-treatment markers in metastatic colorectal cancer(mCRC) treated by cetuximab(Cet) containing chemotherapy. This clinical trial investigated ETS and response rate(RR) in early 8 weeks in KRAS wild-type mCRC treated with mFOLFOX6 plus biweekly Cet in 1st-line chemotherapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
